Castration-resistant prostate cancer: systemic therapy in 2012
Prostate cancer is the most common non-cutaneous neoplasm in the male population worldwide. It is typically diagnosed in its early stages, and the disease exhibits a relatively indolent course in most patients. Despite the curability of localized disease with prostatectomy and radiation therapy, som...
Main Authors: | Fernando C. Maluf, Oren Smaletz, Daniel Herchenhorn |
---|---|
Format: | Article |
Language: | English |
Published: |
Faculdade de Medicina / USP
2012-01-01
|
Series: | Clinics |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322012000400013 |
Similar Items
-
Efficacy of Taxotere, Thalidomide, and Prednisolone in Patients with Hormone-Resistant Metastatic Prostate Cancer
by: Hamid Rezvani, et al.
Published: (2012-11-01) -
Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide
by: Myungsun Shim, et al.
Published: (2019-07-01) -
Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy
by: Kyungchan Min, et al.
Published: (2020-04-01) -
The seventieth anniversary of the hormonal treatment of prostatic carcinoma
by: Milovanović Lela
Published: (2011-01-01) -
Management of advanced prostate cancer Tratamento do câncer de próstata avançado
by: Rafael A. Kaliks, et al.
Published: (2008-04-01)